Analysts Have Conflicting Sentiments on These Healthcare Companies: Radnet (RDNT), Caliber Imaging & Diagnostic (OtherLCDX) and Denali Therapeutics (DNLI)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Radnet (RDNT – Research Report), Caliber Imaging & Diagnostic (LCDX – Research Report) and Denali Therapeutics (DNLI – Research Report).

Radnet (RDNT)

In a report released today, Brian Tanquilut from Jefferies maintained a Buy rating on Radnet, with a price target of $40.00. The company’s shares closed last Wednesday at $31.51, close to its 52-week high of $35.18.

According to TipRanks.com, Tanquilut is a 4-star analyst with an average return of 4.4% and a 52.4% success rate. Tanquilut covers the Healthcare sector, focusing on stocks such as Acadia Healthcare, Tenet Healthcare, and AdaptHealth.

Radnet has an analyst consensus of Strong Buy, with a price target consensus of $39.33, implying a 23.3% upside from current levels. In a report released yesterday, Sidoti also maintained a Buy rating on the stock with a $38.00 price target.

See the top stocks recommended by analysts >>

Caliber Imaging & Diagnostic (LCDX)

In a report released yesterday, Itay Michaeli from Citi maintained a Hold rating on Caliber Imaging & Diagnostic, with a price target of $7.50.

According to TipRanks.com, Michaeli ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -17.7% and a 42.2% success rate. Michaeli covers the Industrial Goods sector, focusing on stocks such as General Motors, American Axle, and GoodYear Tire.

Caliber Imaging & Diagnostic has an analyst consensus of Hold, with a price target consensus of $7.90.

Denali Therapeutics (DNLI)

Jefferies analyst Michael Yee maintained a Buy rating on Denali Therapeutics yesterday and set a price target of $50.00. The company’s shares closed last Wednesday at $24.73.

According to TipRanks.com, Yee is a 3-star analyst with an average return of 1.5% and a 47.2% success rate. Yee covers the Healthcare sector, focusing on stocks such as Olema Pharmaceuticals, Scholar Rock Holding, and Gilead Sciences.

Currently, the analyst consensus on Denali Therapeutics is a Strong Buy with an average price target of $55.11, representing a 94.7% upside. In a report released yesterday, Wedbush also maintained a Buy rating on the stock with a $31.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on RDNT:

• RadNet raises FY23 imaging revenue view to $1.575B-$1.610B from $1.550B-$1.600B
• RadNet reports Q2 EPS 24c, consensus 9c
• RadNet Reports Second Quarter Financial Results, with Record Quarterly Revenue and Adjusted EBITDA(1), and Updates 2023 Financial Guidance Ranges
• RDNT Earnings this Week: How Will it Perform?
• RadNet appoints two executives to lead advancements in technology solutions